The short version of dose escalation fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-12. Anything still debated is marked as such rather than presented as settled.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
They were offered in three shapes (narrow neck, wide mouth, and flat) and multiple sizes, for a total of ten varieties. By 1925, the product line had been limited to a small subset of the original shapes and sizes. In the 1950s an upright Pyrex bottle with a narrow neck was introduced. In the 1960s a wide-neck version was finally introduced to the UK market. The design of upright bottles with a wider mouth meant that they could be more easily cleaned, and sterilized in batches. Soft nipples of various materials were introduced early in the history of feeding (e.g., leather, cork, sponge, dried cow's teat filled with cloth). Many were very difficult to clean and when unsanitary could pose a serious threat to infant health. Although Elijah Pratt of New York patented the first rubber nipple in 1845, it took until the 20th century before materials and technology improved sufficiently to allow manufacture of a soft nipple that was practical for use. The invention of rubber (1840s) provided a material that was soft. Early black Indian rubber "had a very strong pungent smell", and did not survive repeated exposures to hot water. However, by the early 1900s more pleasing rubber nipples could be manufactured in volume and could withstand the heat of sterilization. During the 1940s nurse Adda M. Allen filed for multiple patents relating to the design of baby bottles, including the first disposable collapsible liner for a baby bottle. Her patent was one of many attempts to design a bottle to limit swallowing of air during feeding, and reduce gastric upset and spitting up.
== Experimental method == In cyclic voltammetry (CV), the electrode potential is ramped linearly versus time in cyclical phases. The rate of voltage change over time during each of these phases is known as the scan rate (V/s). In a standard three-electrode cell, the potential is measured between the working electrode and the reference electrode, while the current is measured between the working electrode and the counter electrode. These data are plotted as current density (j, mA/cm2) versus potential (typically corrected for Ohmic/iR drop) (E, V). During the initial forward scan from t0 to t1, an increasingly oxidative (positive) potential is applied, and the anodic (positive) current increases over this time period due to the charging of the electric double layer. The spike in anodic (positive) current observed between t0 and t1 is due to the oxidation of the analyte in the solution when the correct potential is reached. The current decreases after the initial spike as the concentration of oxidable analyte is depleted near the surface of the working electrode due to mass transport limitations. The graph often has a characteristic "duck-like" shape. Comparing the parts of the oxidation and reduction graph portions allows determination of many electrochemical parameters. For example, if the redox couple is reversible, then during the reverse scan (from t1 to t2), the oxidized analyte will start to be re-reduced, giving rise to a cathodic current of opposite polarity.
Dietary minerals, such as potassium, sodium, and iron, are elements native to Earth, and cannot be synthesized. They are required in the diet in microgram or milligram amounts. As plants obtain minerals from the soil, dietary minerals derive directly from plants consumed or indirectly from edible animal sources. Vitamins are organic compounds required in microgram or milligram amounts. The importance of each dietary vitamin was first established when it was determined that a disease would develop if that vitamin was absent from the diet.
=== 1975 leadership election === Heseltine had lost faith in Heath over the second miners' strike and over Heath's personal abrasiveness (Heath had apparently once told him to his face that he was too openly ambitious); his patron Peter Walker had also come to have similar doubts about Heath. Ten days before the October 1974 election, at which Heseltine bucked the national swing by increasing his majority at Henley, he urged Heath to consider his position by the end of the year. It is unclear how Heseltine voted in the first ballot of the 1975 Conservative leadership election, in which the challenger Margaret Thatcher defeated Heath. Norman Tebbit stated that he and John Nott persuaded him to vote for Thatcher so as to open up the way for his preferred candidate Willie Whitelaw to stand on the second ballot. Another (anonymous) close friend later told Michael Crick that Heseltine voted for Thatcher. The Thatcher team had him down as an abstainer, while he refused at the time to reveal how he voted. In his memoirs Heseltine wrote that he abstained in the first ballot, but that he would have voted for Whitelaw in the first ballot had he stood against Heath. Whitelaw admired his drive and energy but looked down on him as "new Money" and is said to have commented that Heseltine was "the sort of man who combs his hair in public". Heseltine toyed with standing himself for the second ballot (in Crick's view his vote would very likely have been derisory), but voted for Whitelaw.
Commonly used spacers and connecting groups include polyether chains, biphenyls and terphenyls, and simple alkyl chains. The chemistry for creating and connecting these units is very well understood. nanoparticles, nanorods, fullerenes and dendrimers offer nanometer-sized structure and encapsulation units. Surfaces can be used as scaffolds for the construction of complex systems and also for interfacing electrochemical systems with electrodes. Regular surfaces can be used for the construction of self-assembled monolayers and multilayers. The understanding of intermolecular interactions in solids has undergone a major renaissance via inputs from different experimental and computational methods in the last decade. This includes high-pressure studies in solids and "in situ" crystallization of compounds which are liquids at room temperature along with the use of electron density analysis, crystal structure prediction and DFT calculations in solid state to enable a quantitative understanding of the nature, energetics and topological properties associated with such interactions in crystals.
Sources: en.wikipedia.org
Cupuaçu trees usually range from 5–15 m (16–49 ft) in height, though some can reach 20 m (66 ft). They have brown bark, and the leaves range from 25–35 cm (9.8–13.8 in) long and 6–10 cm (2.4–3.9 in) across, with 9 or 10 pairs of veins. As the trees mature, the leaves change from pink-tinted to green, and eventually they begin bearing fruit. Flowers of cupuaçu are structurally complex, and require pollination from biotic vectors. The majority of cupuaçu trees are self-incompatible, which can result in decreased pollination levels, and consequently, a decrease in fruit yields. Pollination can also be negatively affected by environmental conditions. Pollinators, which include chrysomelid weevils and stingless bees, are unable to fly between flowers in heavy rains.
MALDI can also detect carbapenemase of carbapenem-resistant enterobacteriaceae, including Acinetobacter baumannii and Klebsiella pneumoniae. However, most proteins that mediate antibiotic resistance are larger than MALDI-TOF's 2000–20,000 Da range for protein peak interpretation and only occasionally, as in the 2011 Klebsiella pneumoniae carbapenemase (KPC) outbreak at the NIH, a correlation between a peak and resistance conferring protein can be made.
== Plant protein research == The first biochemist to enter the field was Karl Heinrich Ritthausen, a student of Justus von Liebig. Thomas Burr Osborne continued what Ritthausen started and published The Vegetable Proteins in 1909. Thus Yale University was the early center of protein nutrition, where William Cumming Rose was a student. Osborne also worked to determine the essentials, and later led the Biochemistry Department at the University of Chicago. When Ritthausen died in 1912, Osborne praised his efforts in biochemistry:
== See also == Phragmen's voting rules – a ballot load balancing method analogous to the idea of Archimedes' principle. Ship stability – Archimedes's theory of displacement of fluid is a core principle of ship stability. List of eponymous laws
=== Adrenal glands === The fetal adrenal cortex can be identified within four weeks of gestation. The adrenal cortex originates from the thickening of the intermediate mesoderm. At five to six weeks of gestation, the mesonephros differentiates into a tissue known as the genital ridge. The genital ridge produces the steroidogenic cells for both the gonads and the adrenal cortex. The adrenal medulla is derived from ectodermal cells. Cells that will become adrenal tissue move retroperitoneally to the upper portion of the mesonephros. At seven weeks of gestation, the adrenal cells are joined by sympathetic cells that originate from the neural crest to form the adrenal medulla. At the end of the eighth week, the adrenal glands have been encapsulated and have formed a distinct organ above the developing kidneys. At birth, the adrenal glands weigh approximately eight to nine grams (twice that of the adult adrenal glands) and are 0.5% of the total body weight. At 25 weeks, the adult adrenal cortex zone develops and is responsible for the primary synthesis of steroids during the early postnatal weeks.
Sources: en.wikipedia.org
== Disorders == The body's hemostasis system requires careful regulation in order to work properly. If the blood does not clot sufficiently, it may be due to bleeding disorders such as hemophilia or immune thrombocytopenia; this requires careful investigation. Over-active clotting can also cause problems; thrombosis, where blood clots form abnormally, can potentially cause embolisms, where blood clots break off and subsequently become lodged in a vein or artery. Hemostasis disorders can develop for many different reasons. They may be congenital, due to a deficiency or defect in an individual's platelets or clotting factors. A number of disorders can be acquired as well, such as in HELLP syndrome, which is due to pregnancy, or Hemolytic-uremic syndrome (HUS), which is due to E. coli toxins.
Audiences at WWE shows have since widely chanted the question during performer promos, and Austin has expressed his surprise at the staying power of the chant, stating in a 2011 interview: "it's been interesting!" Austin's entrance theme was composed by Jim Johnston, who said that in composing the song, he looked upon Austin's persona as an "ass-kicker guy who did not enter a room with subtlety. He needed something that reflected that." Looking to capture the unpredictable nature of the character, Johnston thought of using the sounds of a car crash and smashing glass, and recalled that he instantly felt the theme fit the character and that "it felt like it had already been his theme for years". Austin says the song was inspired by Rage Against the Machine's song "Bulls on Parade". The theme song was revamped in 2000, with the rock band Disturbed recording the new version, used for the first time at the Unforgiven PPV event in September. Austin reverted to the 1998 version of his theme song in December 2001, which he still uses to date. Austin's entrance theme is regarded as one of the greatest of all time, and one which defined the Attitude Era.
=== Stability === Ab initio calculations show that a graphene sheet is thermodynamically unstable if its size is less than about 20 nm and becomes the most stable fullerene (as within graphite) only for molecules larger than 24,000 atoms.
=== Diagnostic use === CRP is used mainly as an inflammation marker. Apart from liver failure, there are few known factors that interfere with CRP production. Interferon alpha inhibits CRP production from liver cells which may explain the relatively low levels of CRP found during viral infections compared to bacterial infections Measuring and charting CRP values can prove useful in determining disease progress or the effectiveness of treatments. ELISA and radial immunodiffusion methods are available for research use, while immunoturbidimetry is used clinically for CRP and nephelometry is typically used for hsCRP. Cutoffs for cardiovascular risk assessment have included:
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.